547 related articles for article (PubMed ID: 32430504)
1. Genetics of progression from MDS to secondary leukemia.
Menssen AJ; Walter MJ
Blood; 2020 Jul; 136(1):50-60. PubMed ID: 32430504
[TBL] [Abstract][Full Text] [Related]
2. Dynamic changes in the clonal structure of MDS and AML in response to epigenetic therapy.
Uy GL; Duncavage EJ; Chang GS; Jacoby MA; Miller CA; Shao J; Heath S; Elliott K; Reineck T; Fulton RS; Fronick CC; O'Laughlin M; Ganel L; Abboud CN; Cashen AF; DiPersio JF; Wilson RK; Link DC; Welch JS; Ley TJ; Graubert TA; Westervelt P; Walter MJ
Leukemia; 2017 Apr; 31(4):872-881. PubMed ID: 27740633
[TBL] [Abstract][Full Text] [Related]
3. Convergent Clonal Evolution of Signaling Gene Mutations Is a Hallmark of Myelodysplastic Syndrome Progression.
Menssen AJ; Khanna A; Miller CA; Nonavinkere Srivatsan S; Chang GS; Shao J; Robinson J; O'Laughlin M; Fronick CC; Fulton RS; Brendel K; Heath SE; Saba R; Welch JS; Spencer DH; Payton JE; Westervelt P; DiPersio JF; Link DC; Schuelke MJ; Jacoby MA; Duncavage EJ; Ley TJ; Walter MJ
Blood Cancer Discov; 2022 Jul; 3(4):330-345. PubMed ID: 35709710
[TBL] [Abstract][Full Text] [Related]
4. Gene mutations and clonal architecture in myelodysplastic syndromes and changes upon progression to acute myeloid leukaemia and under treatment.
Stosch JM; Heumüller A; Niemöller C; Bleul S; Rothenberg-Thurley M; Riba J; Renz N; Szarc Vel Szic K; Pfeifer D; Follo M; Pahl HL; Zimmermann S; Duyster J; Wehrle J; Lübbert M; Metzeler KH; Claus R; Becker H
Br J Haematol; 2018 Sep; 182(6):830-842. PubMed ID: 29974943
[TBL] [Abstract][Full Text] [Related]
5. Epigenetic priming with decitabine followed by low dose idarubicin and cytarabine in acute myeloid leukemia evolving from myelodysplastic syndromes and higher-risk myelodysplastic syndromes: a prospective multicenter single-arm trial.
Zhou X; Mei C; Zhang J; Lu Y; Lan J; Lin S; Zhang Y; Kuang Y; Ren Y; Ma L; Wei J; Ye L; Xu W; Li K; Lu C; Jin J; Tong H
Hematol Oncol; 2020 Oct; 38(4):531-540. PubMed ID: 32469434
[TBL] [Abstract][Full Text] [Related]
6. Genetics of MDS.
Ogawa S
Blood; 2019 Mar; 133(10):1049-1059. PubMed ID: 30670442
[TBL] [Abstract][Full Text] [Related]
7. Clonal architecture of secondary acute myeloid leukemia.
Walter MJ; Shen D; Ding L; Shao J; Koboldt DC; Chen K; Larson DE; McLellan MD; Dooling D; Abbott R; Fulton R; Magrini V; Schmidt H; Kalicki-Veizer J; O'Laughlin M; Fan X; Grillot M; Witowski S; Heath S; Frater JL; Eades W; Tomasson M; Westervelt P; DiPersio JF; Link DC; Mardis ER; Ley TJ; Wilson RK; Graubert TA
N Engl J Med; 2012 Mar; 366(12):1090-8. PubMed ID: 22417201
[TBL] [Abstract][Full Text] [Related]
8. Mutations of myelodysplastic syndromes (MDS): An update.
Ganguly BB; Kadam NN
Mutat Res Rev Mutat Res; 2016; 769():47-62. PubMed ID: 27543316
[TBL] [Abstract][Full Text] [Related]
9. Clonal selection in therapy-related myelodysplastic syndromes and acute myeloid leukemia under azacitidine treatment.
Calleja A; Yun S; Moreilhon C; Karsenti JM; Gastaud L; Mannone L; Komrokji R; Al Ali N; Dadone-Montaudie B; Robert G; Auberger P; Raynaud S; Sallman DA; Cluzeau T
Eur J Haematol; 2020 May; 104(5):488-498. PubMed ID: 31990086
[TBL] [Abstract][Full Text] [Related]
10. Aberrant DNA methylation is a dominant mechanism in MDS progression to AML.
Jiang Y; Dunbar A; Gondek LP; Mohan S; Rataul M; O'Keefe C; Sekeres M; Saunthararajah Y; Maciejewski JP
Blood; 2009 Feb; 113(6):1315-25. PubMed ID: 18832655
[TBL] [Abstract][Full Text] [Related]
11. Molecular Pathogenesis and Treatment of Myelodysplastic Syndromes.
Nakajima H
Intern Med; 2021 Jan; 60(1):15-23. PubMed ID: 32009100
[TBL] [Abstract][Full Text] [Related]
12. Genetic basis of myelodysplastic syndromes.
Ogawa S
Proc Jpn Acad Ser B Phys Biol Sci; 2020; 96(3):107-121. PubMed ID: 32161209
[TBL] [Abstract][Full Text] [Related]
13. [Research progress on mechanism of MDS transformation into AML].
Wang LL; Gao C; Chen BA
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2011 Feb; 19(1):254-9. PubMed ID: 21362264
[TBL] [Abstract][Full Text] [Related]
14. Myelodysplastic Syndromes: How to Recognize Risk and Avoid Acute Myeloid Leukemia Transformation.
Hospital MA; Vey N
Curr Oncol Rep; 2020 Jan; 22(1):4. PubMed ID: 31974774
[TBL] [Abstract][Full Text] [Related]
15. The Genetic Landscape of Myelodysplastic Neoplasm Progression to Acute Myeloid Leukemia.
Bănescu C; Tripon F; Muntean C
Int J Mol Sci; 2023 Mar; 24(6):. PubMed ID: 36982819
[TBL] [Abstract][Full Text] [Related]
16. The changing mutational landscape of acute myeloid leukemia and myelodysplastic syndrome.
Larsson CA; Cote G; Quintás-Cardama A
Mol Cancer Res; 2013 Aug; 11(8):815-27. PubMed ID: 23645565
[TBL] [Abstract][Full Text] [Related]
17. Myelodysplastic syndrome progression to acute myeloid leukemia at the stem cell level.
Chen J; Kao YR; Sun D; Todorova TI; Reynolds D; Narayanagari SR; Montagna C; Will B; Verma A; Steidl U
Nat Med; 2019 Jan; 25(1):103-110. PubMed ID: 30510255
[TBL] [Abstract][Full Text] [Related]
18. Cell-lineage level-targeted sequencing to identify acute myeloid leukemia with myelodysplasia-related changes.
Yokoyama K; Shimizu E; Yokoyama N; Nakamura S; Kasajima R; Ogawa M; Takei T; Ito M; Kobayashi A; Yamaguchi R; Imoto S; Miyano S; Tojo A
Blood Adv; 2018 Oct; 2(19):2513-2521. PubMed ID: 30282643
[TBL] [Abstract][Full Text] [Related]
19. Understanding the Continuum between High-Risk Myelodysplastic Syndrome and Acute Myeloid Leukemia.
Zavras PD; Sinanidis I; Tsakiroglou P; Karantanos T
Int J Mol Sci; 2023 Mar; 24(5):. PubMed ID: 36902450
[TBL] [Abstract][Full Text] [Related]
20. Mutational profiling of therapy-related myelodysplastic syndromes and acute myeloid leukemia by next generation sequencing, a comparison with de novo diseases.
Ok CY; Patel KP; Garcia-Manero G; Routbort MJ; Fu B; Tang G; Goswami M; Singh R; Kanagal-Shamanna R; Pierce SA; Young KH; Kantarjian HM; Medeiros LJ; Luthra R; Wang SA
Leuk Res; 2015 Mar; 39(3):348-54. PubMed ID: 25573287
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
